Roles
- Professor of Neurology
- Chief, Division of Cognitive Neurology
- Director, Comprehensive Center for Brain Health
- Director, Lewy Body Dementia Research Center of Excellence
-
Biography
James E. Galvin, M.D., M.P.H. is Professor of Neurology and Psychiatry & Behavioral Sciences at the University of Miami Miller School of Medicine. He is Division Chief for Cognitive Neurology, Founding Director of the Comprehensive Center for Brain Health, and Director and Principal Investigator of the Lewy Body Dementia Research Center of Excellence. Dr. Galvin has authored over 325 scientific publications (h-index=66) and 3 textbooks on healthy brain aging, cognitive health, Alzheimer’s disease, Lewy Body dementia, and related disorders. Dr. Galvin is principal investigator on 9 active NIH grants and has received over $100 Million in research funding from the National Institutes of Health, Disease Associations, Private and Family Foundations. -
Education & Training
Education
Post Graduate Training
Licensures and Certifications
-
Teaching Interests
Dr Galvin and his colleagues at the Comprehensive Center for Brain Health (CCBH) develop unique training opportunities for students, residents, fellows, staff, and faculty to gain training, knowledge, and expertise in brain health and neurodegenerative diseases and provide structured mentoring opportunities for early-stage investigators on their path to research independence. CCBH also is actively involved in training the next generation of clinicians and scientists and providing educational programming for the lay community. In the past 2 years, CCBH has conducted over 60 programs reaching over 4000 individuals. -
Research Interests
The Comprehensive Center for Brain Health (CCBH), part of the Department of Neurology at the University of Miami Miller School of Medicine, was created to provide a robust and collaborative infrastructure to study brain health and the risk of neurodegenerative diseases such as Mild Cognitive Impairment, Alzheimer’s Disease, Parkinson’s Disease, Lewy Body Dementia, Frontotemporal Degeneration, Vascular Cognitive Impairment, and Chronic Traumatic Encephalopathy. CCBH uses a transdisciplinary approach for our research projects and clinical care, combining the best practices of neurology, gerontology, cognitive neuroscience, nursing, social work, psychotherapy, integrative nutrition, mindfulness, lifestyle modification, physical therapy, public health, medical education, epidemiology, biochemistry, genetics, data science, and biostatistics. In addition to our NIH-funded research, CCBH has a comprehensive clinical arm to evaluate, diagnosis and treat individuals with all forms of cognitive impairment, providing a personalized and tailored approach to brain health with a focus of improving the healthspan for all our patients.
The Healthy Brain Initiative (HBI) Project is at the heart of CCBH’s mission. Funded by multiple federal and private grants, HBI is a longitudinal study to deeply phenotype individuals, determine factors that contribute the cognitive resilience and healthy brain aging, examine factors that increase vulnerability and risk of neurodegenerative disease, and explore social and medical determinants of brain health in diverse populations including African Americans, Afro-Caribbeans, Hispanics, rural communities, American Indians, Native Hawaiians, and Pacific Islanders. The ultimate goal of HBI is to develop dementia prevention programs using a precision medicine-like approach with personalized tailored interventions by combining innovative implementation of culturally adapted health literacy assessments alongside comprehensive “phenotype-to-genotype” community-based healthcare research. HBI supports a number of affiliated studies in Lewy Body Dementia, Alzheimer's disease, and mild cognitive impairment, including pragmatic studies using electronic health records and patient-reported outcomes, qualitative research on health disparities and stigma, creation of novel plasma and behavior-based biomarkers of neurodegenerative disease, and testing novel therapeutics and diagnostics. -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Articles & News
Two Research Awards Advance Blood-Based Epigenetics Studies of Cognitive Aging and Dementia
Blood Biomarker May Signal Memory Vulnerability Years Before Cognitive Changes
University of Miami Researchers Showcase Advances in Dementia Detection, Treatment and Brain Health at AAIC 2026
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 10 clinical trials.
-
The purpose of this study is to define a noninvasive method for the early detection of Alzheimers disease and related dementia in routine clinical practice or large population screenings. Since the cerebral cortex of the brain and the retina share a similar structure and function, pathological changes seen in the brain of patients with ADRD are likely to be present in the retina. Given that the retina is the most accessible part of the brain and allows noninvasive testing of ocular biomarkers, like neurodegeneration, in a clinical setting, our hope is that such testing will offer an innovative solution to the drawbacks encountered with standard brain imaging.
- Principal Investigator: James Galvin
- Study Phase: TBD
- Enrollment Status: Open
-
This study aims to understand what changes might predict the end of life in people with dementia with Lewy bodies (DLB). This information will help patients, caregivers, families, and health care professionals know what to expect in later stages of DLB. It will also help identify what changes might suggest that someone is approaching the end of life, and how to make that time a good experience.
- Principal Investigator: James Galvin
- Study Phase: TBD
- Enrollment Status: Open
-
The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's
- Principal Investigator: James Galvin
- Study Phase: Phase 2
- Enrollment Status: Not Accepting
-
A study involving a comprehensive assessment of Dementia with Lewy Bodies.
- Principal Investigator: James Galvin
- Study Phase: N/A
- Enrollment Status: Closed
-
The Clinical Validation study is aimed at early detection of Alzheimers Disease and Related Dementia (ADRD) through early screening in older adults aged 65 years and older. Possible participants will be identified and the research team will conduct ADRD screening on all eligible patients. ADRD assessments will be performed. We anticipate early detection of ADRD in some patients enrolled in this study, whoundergo the screening process. Patients enrolled in the study who screen positive for ADRD will be referred for further appropriate diagnostic testing if they are interested.
- Principal Investigator: James Galvin
- Study Phase: N/A
- Enrollment Status: Not Accepting
-
The purpose of this study is to define a noninvasive method for the early detection of Alzheimers disease and related dementia in routine clinical practice or large population screenings. Since the cerebral cortex of the brain and the retina share a similar structure and function, pathological changes seen in the brain of patients with ADRD are likely to be present in the retina. Given that the retina is the most accessible part of the brain and allows noninvasive testing of ocular biomarkers, like neurodegeneration, in a clinical setting, our hope is that such testing will offer an innovative solution to the drawbacks encountered with standard brain imaging.
- Principal Investigator: James Galvin
- Study Phase: TBD
- Enrollment Status: Open
-
This study aims to understand what changes might predict the end of life in people with dementia with Lewy bodies (DLB). This information will help patients, caregivers, families, and health care professionals know what to expect in later stages of DLB. It will also help identify what changes might suggest that someone is approaching the end of life, and how to make that time a good experience.
- Principal Investigator: James Galvin
- Study Phase: TBD
- Enrollment Status: Open
-
The Clinical Validation study is aimed at early detection of Alzheimers Disease and Related Dementia (ADRD) through early screening in older adults aged 65 years and older. Possible participants will be identified and the research team will conduct ADRD screening on all eligible patients. ADRD assessments will be performed. We anticipate early detection of ADRD in some patients enrolled in this study, whoundergo the screening process. Patients enrolled in the study who screen positive for ADRD will be referred for further appropriate diagnostic testing if they are interested.
- Principal Investigator: James Galvin
- Study Phase: N/A
- Enrollment Status: Not Accepting
-
The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's
- Principal Investigator: James Galvin
- Study Phase: Phase 2
- Enrollment Status: Not Accepting
-
A study involving a comprehensive assessment of Dementia with Lewy Bodies.
- Principal Investigator: James Galvin
- Study Phase: N/A
- Enrollment Status: Closed
